Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neuroendocrine Tumors 40 Gastro-enteropancreatic neuroendocrine tumor 8 Paraganglioma 6 Meningioma 6 Pheochromocytoma 5 Carcinoma, Neuroendocrine 4 Neuroblastoma 3 Carcinoid Tumor 3 Adenoma, Islet Cell 3 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Neoplasms 2 Medulloblastoma 2 Glioma 2 Glioblastoma 2 Ependymoma 2 Carcinoma, Merkel Cell 2 Carcinoma, Medullary 2 Stomach Neoplasms 1 Somatostatinoma 1 Somatostatin Receptor-positive Neuroendocrine Tumor 1 Somatostatin Receptor-positive GEP-NET 1 Small Cell Lung Carcinoma 1 Serotonin Syndrome 1 Sarcoma, Synovial 1 Recurrence 1 Pituitary Neoplasms 1 Parathyroid Neoplasms 1 Pancreatic Diseases 1

Interventions

Capecitabine 6 Temozolomide 5 Octreotide 4 Leucovorin 4 Everolimus 4 Fluorouracil 3 Bevacizumab 3 vatalanib 2 pentetreotide 2 Trastuzumab 2 Sunitinib 2 Oxaliplatin 2 Magnetic Resonance Spectroscopy 2 Cisplatin 2 Bortezomib 2 Biological Therapy 2 veliparib 1 tipifarnib 1 temsirolimus 1 sapanisertib 1 romidepsin 1 regorafenib 1 pazopanib 1 palbociclib 1 motesanib diphosphate 1 lutetium Lu 177 dotatate 1 irinotecan sucrosofate 1 gallium Ga 68 dotatate 1 dehydroftorafur 1 cixutumumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Somatostatinoma × lutetium Lu 177 dotatate × Clear all

NCT02230176 2025-04-20

OCCLURANDOM

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡